ArticlePacific Symposium on Biocomputing. Pacific Symposium on Biocomputing2025
Multi-modal Imaging-based Pseudotime Analysis of Alzheimer progression.
Article in Pacific Symposium on Biocomputing. Pacific Symposium on Biocomputing, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Associations of stable psychological traits with multi-omic subtypes of Alzheimer's dementia.Translational psychiatry · 2026Article
- Learning a Continuous Progression Trajectory of Amyloid in Alzheimer disease.bioRxiv : the preprint server for biology · 2026Article
- Mapping cellular interactions and communication landscapes in cervical cancer via single-cell transcriptomics.Discover oncology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Alzheimer's disease (AD) is a neurodegenerative disorder that results in progressive cognitive decline but without any clinically validated cures so far. Understanding the progression of AD is critical for early detection and risk assessment for AD in aging individuals, thereby enabling initiation of timely intervention and improved chance of success in AD trials. Recent pseudotime approach turns cross-sectional data into "faux" longitudinal data to understand how a complex process evolves over time. This is critical for Alzheimer, which unfolds over the course of decades, but the collected data offers only a snapshot. In this study, we tested several state-of-the-art pseudotime approaches to model the full spectrum of AD progression. Subsequently, we evaluated and compared the pseudotime progression score derived from individual imaging modalities and multi-modalities in the ADNI cohort. Our results showed that most existing pseudotime analysis tools do not generalize well to the imaging data, with either flipped progression score or poor separation of diagnosis groups. This is likely due to the underlying assumptions that only stand for single cell data. From the only tool with promising results, it was observed that all pseudotime, derived from either single imaging modalities or multi-modalities, captures the progressiveness of diagnosis groups. Pseudotime from multi-modality, but not the single modalities, confirmed the hypothetical temporal order of imaging phenotypes. In addition, we found that multi-modal pseudotime is mostly driven by amyloid and tau imaging, suggesting their continuous changes along the full spectrum of AD progression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.